ルノー カングー ゼン 1.6 新車ご成約ありがとうございます
2017年02月20日
神奈川県 横浜市
Ｆ様
ルノー カングー １．６ ゼン 新車
ご成約ありがとうございます
Ｆ様
この度も弊社よりご購入誠にありがとうございます
今回もディーラーお見積もりより安い！
ＲＧスペシャル価格にてご案内させて頂きます！
これからカスタマイズに入りますので
ご納車まで今しばらくお待ちください
担当 齊藤
この記事へのコメント
(Ronda)
Sustanon Genopharm, Anadrol And Dbol Stack ?一體育
Part?1 ? What anabolic steroids such as nandrolone
are and how they work
Anabolic?steroid drugs are synthetic versions of the hormone testosterone.
Nandrolone is one of these compounds that has a stronger "anabolic" (muscle?building) effect than its natural counterpart.
When you inject or otherwise take it, the drug enters your bloodstream and reaches the cells in muscles and bone.
Inside those cells it binds to specific receptors,
which then trigger processes that increase protein synthesis ?
the building blocks of muscle tissue. In addition, nandrolone can encourage the
body to keep more red blood cells alive and to reduce
the loss of them from exercise or injury.
Because of these actions, people who use nandrolone often see their muscles grow faster and recover more quickly after hard training.
The drug also has a mild effect on bone density, helping
the skeleton stay stronger during periods when you might
be limiting weight?bearing activity for medical reasons.
---
How it Works When You’re In Bed Rest
When your body is forced into bed rest ? usually because of a
serious illness or injury that makes moving painful or unsafe ? the muscles and bones
that would normally get their daily workout are essentially idle.
The longer they stay inactive, the quicker they begin to weaken: muscle fibers shrink, bone mineral density drops,
and joint stiffness can set in.
Here’s how a drug like this helps:
Physiological Effect What Happens Normally During Bed Rest?
How the Drug Counteracts It
Muscle Mass & Strength Without mechanical load, proteins that maintain muscle are broken down more than they’re built.
The drug reduces protein breakdown and stimulates new muscle protein synthesis (via
anabolic signaling).
Bone Density Bone remodeling shifts toward resorption; osteoclast activity dominates because of low mechanical stimulus.
It suppresses bone-resorbing cells (osteoclasts) while preserving or modestly stimulating bone-forming cells (osteoblasts).
Nervous System & Motor Control Prolonged inactivity leads to reduced motor neuron excitability and changes
in proprioception. The drug may enhance neurotransmitter pathways,
supporting neuronal health and maintaining neuromuscular junction integrity.
---
2. What the drug actually does (and how it might help)
Target Primary Effect of the Drug Likely Clinical Benefit
Skeletal muscle Inhibits protein breakdown by blocking ubiquitin?proteasome signaling; modestly upregulates anabolic pathways
(e.g., mTOR). Preserves lean mass, improves strength and
functional performance.
Bone matrix Modulates osteoblast/osteoclast
activity?promotes bone formation, reduces resorption markers.
Decreases fracture risk, maintains bone mineral density.
Cardiovascular system Lowers blood pressure, improves endothelial function; may reduce arterial stiffness.
Improves overall cardiovascular health, reduces morbidity/mortality.
Metabolic profile Enhances insulin sensitivity,
lowers fasting glucose and triglycerides. Benefits individuals with metabolic syndrome or diabetes.
---
3. Current Evidence Base
4.1 Systematic Reviews & Meta?Analyses (2015?2024)
Review/Meta?Analysis Design Population Key Findings
Smith et?al., JAMA Netw Open, 2018 Randomized controlled trials (RCTs) of plant?based diets for weight loss Adults, BMI
?25 Plant?based diet led to an average 4.2?kg greater weight loss vs control
over 6 months
Lee et?al., Cochrane Database Syst Rev, 2020 RCTs on dietary patterns and cardiometabolic outcomes Adults with metabolic syndrome
Plant?based diet reduced systolic BP by 5?mmHg (95% CI:
?8 to ?2)
Perez?Martinez et?al., Nutrition Reviews, 2021 Observational studies
on mortality Adults, 10?year follow?up
Higher plant?based dietary score associated with
12% lower all?cause mortality
García?Sánchez et?al., Journal of Clinical Nutrition, 2022 RCTs on weight loss and appetite control Overweight
adults Plant?based diet yielded 1.5?kg greater weight loss over 6?weeks (p=0.01)
Key points from the literature
Domain Effect size / evidence
Weight management Diets high in vegetables & legumes → >1?2?kg greater loss vs control
(short?term).
Satiety / appetite High fiber & protein → lower hunger ratings, delayed gastric emptying.
Metabolic health Improved fasting glucose, triglycerides, and LDL cholesterol; reduced insulin resistance.
Sustainability Participants report easier adherence due to variety and low cost.
---
3. Practical meal?planning framework
3.1 Overall strategy
Goal Implementation
Macronutrient balance Target: ~30?% protein, 25?35?% fat (mostly
unsaturated), 40?45?% carbs (mostly complex).
Caloric deficit Estimate TDEE (~2200?2400 kcal for a moderately active 70?kg adult); set intake at ~1800?1900 kcal.
Fiber & micronutrients Aim for ?30 g fiber, 400?mg potassium, 120?mg magnesium per day.
Meal timing 3 balanced meals + 1-2 snacks (e.g., 12?pm, 4?pm, 7?pm).
Hydration 2?2.5 L water/day.
Example Daily Menu
Time Meal / Snack Composition
10:00?am Breakfast Greek yogurt (200?g) + 30?g granola + 50?g mixed berries + 1
tsp honey
12:00?pm Lunch Grilled chicken breast (150?g) + quinoa salad (100?g cooked
quinoa, cucumber, tomato, olives, lemon vinaigrette) + 1 small apple
3:30?pm Snack Handful of raw almonds (25?g) + a handful of baby carrots
6:00?pm Dinner Baked salmon fillet (140?g) + roasted sweet potato (150?g) + steamed broccoli (100?g) + drizzle olive
oil
8:30?pm Snack Greek yogurt (150?g) with honey
and a sprinkle of chia seeds
This menu covers about 2,000?2,200 kcal and supplies ~100 g protein, ~70 g fat,
~260 g carbs, and a healthy mix of micronutrients. Adjust portions up or down if you need more or
fewer calories.
---
4?? The "No?Plan" Approach ? What to Watch For
Risk of Energy Deficit
Even with good food choices, if the total intake falls below your TDEE you’ll
lose weight (fat and muscle). Without a plan, many people inadvertently consume too few calories
because they focus on "clean eating" or portion control without tracking.
Protein Sparsity
Studies show that protein needs for maintaining lean mass during caloric restriction are ~1.6?2.0?g/kg/day in active adults.
A "free?form" diet may provide less than this if you’re not mindful, especially on low?calorie days.
Rebound Eating
The psychological effect of "strict" dieting often leads to
periods of binge or overeating. Structured plans (meal prep,
scheduled calorie allowances) can mitigate this by
providing clear guidelines.
Micronutrient Gaps
Even with balanced macro ratios, free?form diets
may miss certain micronutrients (e.g., vitamin D,
omega?3 fatty acids). A structured plan can incorporate fortified
foods or supplements to cover these.
How a Structured Plan Can Address These Issues
Issue Structured Approach Example
Calorie deficit Set daily kcal target based on TDEE and desired loss (e.g., 500?kcal) 2000?kcal/day with
1500?kcal/goal
Macronutrient balance Use percentages to calculate grams of protein, carbs, fats
30% protein = 150?g; 40% carbs = 200?g; 30% fat = 67?g
Meal timing Plan meals around workout for energy and
recovery Pre?workout: banana + whey; Post?workout:
chicken & rice
Progress tracking Weekly weigh?ins, body measurements, progress
photos Log weight, waist circumference each Monday
---
5. Sample Meal Plan (??1?600?kcal)
Time Food Item Calories Protein (g) Carbs (g) Fat
(g)
Breakfast Greek yogurt (200?g) + honey (1?Tbsp) +
mixed berries (100?g) 250 20 35 3
Oatmeal (40?g rolled oats) cooked in water, topped with sliced banana
(50?g) 150 5 30 2
Mid?morning Snack Apple (medium) + peanut butter (1?Tbsp) 190 4 25
10
Lunch Grilled chicken breast (120?g) with quinoa salad:
quinoa (50?g cooked), cherry tomatoes, cucumber, olive oil
& lemon dressing 400 35 45 12
Afternoon Snack Greek yogurt (125?g) with mixed berries (60?g) and honey (1?tsp) 170 10 25 3
Dinner Baked salmon (120?g) with roasted sweet potato (100?g) and
steamed broccoli (80?g) 350 30 40 8
Evening Snack Apple slices (1 medium apple) with peanut butter
(1?Tbsp) 200 6 25 12
---
Total Daily Intake
Nutrient Total (kcal) Calories from Protein Calories from Fat Calories from Carbs
Energy 2,652 kcal 1,200 kcal (45%) 700 kcal (26.4%) 752 kcal (28.4%)
Protein: ~240 g (960 kcal) ? 36% of total energy
Fat: ~77 g (700 kcal) ? 26% of total energy
Carbohydrates: ~188 g (752 kcal) ? 28% of total energy
Nutrient distribution:
The macro?distribution is within the ranges recommended by most sports nutrition guidelines for athletes in a
heavy training phase: high protein to support muscle repair,
moderate fat to provide essential fatty acids and satiety,
and enough carbohydrates to fuel intense workouts while preserving glycogen stores.
Adjustments can be made based on individual tolerance or specific periodization goals (e.g., slightly higher carbs pre?competition).
Implementation tips:
Meal timing ? Distribute protein across 4?6 meals, with ~20?25?g of high?quality protein per meal
for optimal muscle protein synthesis.
Recovery snack ? A post?training carbohydrate + protein combo (e.g., whey shake
+ banana) helps replenish glycogen and stimulate
repair within the anabolic window (~30?min).
Hydration & electrolytes ? Monitor sweat loss; supplement with sodium, potassium, and magnesium during heavy training days.
By following this plan, you’ll align your macronutrient intake with your training load, promoting muscle growth
while preventing excess fat gain. Adjust portion sizes as
needed based on body composition feedback every 4?6?weeks.
Good luck!
Part?1 ? What anabolic steroids such as nandrolone
are and how they work
Anabolic?steroid drugs are synthetic versions of the hormone testosterone.
Nandrolone is one of these compounds that has a stronger "anabolic" (muscle?building) effect than its natural counterpart.
When you inject or otherwise take it, the drug enters your bloodstream and reaches the cells in muscles and bone.
Inside those cells it binds to specific receptors,
which then trigger processes that increase protein synthesis ?
the building blocks of muscle tissue. In addition, nandrolone can encourage the
body to keep more red blood cells alive and to reduce
the loss of them from exercise or injury.
Because of these actions, people who use nandrolone often see their muscles grow faster and recover more quickly after hard training.
The drug also has a mild effect on bone density, helping
the skeleton stay stronger during periods when you might
be limiting weight?bearing activity for medical reasons.
---
How it Works When You’re In Bed Rest
When your body is forced into bed rest ? usually because of a
serious illness or injury that makes moving painful or unsafe ? the muscles and bones
that would normally get their daily workout are essentially idle.
The longer they stay inactive, the quicker they begin to weaken: muscle fibers shrink, bone mineral density drops,
and joint stiffness can set in.
Here’s how a drug like this helps:
Physiological Effect What Happens Normally During Bed Rest?
How the Drug Counteracts It
Muscle Mass & Strength Without mechanical load, proteins that maintain muscle are broken down more than they’re built.
The drug reduces protein breakdown and stimulates new muscle protein synthesis (via
anabolic signaling).
Bone Density Bone remodeling shifts toward resorption; osteoclast activity dominates because of low mechanical stimulus.
It suppresses bone-resorbing cells (osteoclasts) while preserving or modestly stimulating bone-forming cells (osteoblasts).
Nervous System & Motor Control Prolonged inactivity leads to reduced motor neuron excitability and changes
in proprioception. The drug may enhance neurotransmitter pathways,
supporting neuronal health and maintaining neuromuscular junction integrity.
---
2. What the drug actually does (and how it might help)
Target Primary Effect of the Drug Likely Clinical Benefit
Skeletal muscle Inhibits protein breakdown by blocking ubiquitin?proteasome signaling; modestly upregulates anabolic pathways
(e.g., mTOR). Preserves lean mass, improves strength and
functional performance.
Bone matrix Modulates osteoblast/osteoclast
activity?promotes bone formation, reduces resorption markers.
Decreases fracture risk, maintains bone mineral density.
Cardiovascular system Lowers blood pressure, improves endothelial function; may reduce arterial stiffness.
Improves overall cardiovascular health, reduces morbidity/mortality.
Metabolic profile Enhances insulin sensitivity,
lowers fasting glucose and triglycerides. Benefits individuals with metabolic syndrome or diabetes.
---
3. Current Evidence Base
4.1 Systematic Reviews & Meta?Analyses (2015?2024)
Review/Meta?Analysis Design Population Key Findings
Smith et?al., JAMA Netw Open, 2018 Randomized controlled trials (RCTs) of plant?based diets for weight loss Adults, BMI
?25 Plant?based diet led to an average 4.2?kg greater weight loss vs control
over 6 months
Lee et?al., Cochrane Database Syst Rev, 2020 RCTs on dietary patterns and cardiometabolic outcomes Adults with metabolic syndrome
Plant?based diet reduced systolic BP by 5?mmHg (95% CI:
?8 to ?2)
Perez?Martinez et?al., Nutrition Reviews, 2021 Observational studies
on mortality Adults, 10?year follow?up
Higher plant?based dietary score associated with
12% lower all?cause mortality
García?Sánchez et?al., Journal of Clinical Nutrition, 2022 RCTs on weight loss and appetite control Overweight
adults Plant?based diet yielded 1.5?kg greater weight loss over 6?weeks (p=0.01)
Key points from the literature
Domain Effect size / evidence
Weight management Diets high in vegetables & legumes → >1?2?kg greater loss vs control
(short?term).
Satiety / appetite High fiber & protein → lower hunger ratings, delayed gastric emptying.
Metabolic health Improved fasting glucose, triglycerides, and LDL cholesterol; reduced insulin resistance.
Sustainability Participants report easier adherence due to variety and low cost.
---
3. Practical meal?planning framework
3.1 Overall strategy
Goal Implementation
Macronutrient balance Target: ~30?% protein, 25?35?% fat (mostly
unsaturated), 40?45?% carbs (mostly complex).
Caloric deficit Estimate TDEE (~2200?2400 kcal for a moderately active 70?kg adult); set intake at ~1800?1900 kcal.
Fiber & micronutrients Aim for ?30 g fiber, 400?mg potassium, 120?mg magnesium per day.
Meal timing 3 balanced meals + 1-2 snacks (e.g., 12?pm, 4?pm, 7?pm).
Hydration 2?2.5 L water/day.
Example Daily Menu
Time Meal / Snack Composition
10:00?am Breakfast Greek yogurt (200?g) + 30?g granola + 50?g mixed berries + 1
tsp honey
12:00?pm Lunch Grilled chicken breast (150?g) + quinoa salad (100?g cooked
quinoa, cucumber, tomato, olives, lemon vinaigrette) + 1 small apple
3:30?pm Snack Handful of raw almonds (25?g) + a handful of baby carrots
6:00?pm Dinner Baked salmon fillet (140?g) + roasted sweet potato (150?g) + steamed broccoli (100?g) + drizzle olive
oil
8:30?pm Snack Greek yogurt (150?g) with honey
and a sprinkle of chia seeds
This menu covers about 2,000?2,200 kcal and supplies ~100 g protein, ~70 g fat,
~260 g carbs, and a healthy mix of micronutrients. Adjust portions up or down if you need more or
fewer calories.
---
4?? The "No?Plan" Approach ? What to Watch For
Risk of Energy Deficit
Even with good food choices, if the total intake falls below your TDEE you’ll
lose weight (fat and muscle). Without a plan, many people inadvertently consume too few calories
because they focus on "clean eating" or portion control without tracking.
Protein Sparsity
Studies show that protein needs for maintaining lean mass during caloric restriction are ~1.6?2.0?g/kg/day in active adults.
A "free?form" diet may provide less than this if you’re not mindful, especially on low?calorie days.
Rebound Eating
The psychological effect of "strict" dieting often leads to
periods of binge or overeating. Structured plans (meal prep,
scheduled calorie allowances) can mitigate this by
providing clear guidelines.
Micronutrient Gaps
Even with balanced macro ratios, free?form diets
may miss certain micronutrients (e.g., vitamin D,
omega?3 fatty acids). A structured plan can incorporate fortified
foods or supplements to cover these.
How a Structured Plan Can Address These Issues
Issue Structured Approach Example
Calorie deficit Set daily kcal target based on TDEE and desired loss (e.g., 500?kcal) 2000?kcal/day with
1500?kcal/goal
Macronutrient balance Use percentages to calculate grams of protein, carbs, fats
30% protein = 150?g; 40% carbs = 200?g; 30% fat = 67?g
Meal timing Plan meals around workout for energy and
recovery Pre?workout: banana + whey; Post?workout:
chicken & rice
Progress tracking Weekly weigh?ins, body measurements, progress
photos Log weight, waist circumference each Monday
---
5. Sample Meal Plan (??1?600?kcal)
Time Food Item Calories Protein (g) Carbs (g) Fat
(g)
Breakfast Greek yogurt (200?g) + honey (1?Tbsp) +
mixed berries (100?g) 250 20 35 3
Oatmeal (40?g rolled oats) cooked in water, topped with sliced banana
(50?g) 150 5 30 2
Mid?morning Snack Apple (medium) + peanut butter (1?Tbsp) 190 4 25
10
Lunch Grilled chicken breast (120?g) with quinoa salad:
quinoa (50?g cooked), cherry tomatoes, cucumber, olive oil
& lemon dressing 400 35 45 12
Afternoon Snack Greek yogurt (125?g) with mixed berries (60?g) and honey (1?tsp) 170 10 25 3
Dinner Baked salmon (120?g) with roasted sweet potato (100?g) and
steamed broccoli (80?g) 350 30 40 8
Evening Snack Apple slices (1 medium apple) with peanut butter
(1?Tbsp) 200 6 25 12
---
Total Daily Intake
Nutrient Total (kcal) Calories from Protein Calories from Fat Calories from Carbs
Energy 2,652 kcal 1,200 kcal (45%) 700 kcal (26.4%) 752 kcal (28.4%)
Protein: ~240 g (960 kcal) ? 36% of total energy
Fat: ~77 g (700 kcal) ? 26% of total energy
Carbohydrates: ~188 g (752 kcal) ? 28% of total energy
Nutrient distribution:
The macro?distribution is within the ranges recommended by most sports nutrition guidelines for athletes in a
heavy training phase: high protein to support muscle repair,
moderate fat to provide essential fatty acids and satiety,
and enough carbohydrates to fuel intense workouts while preserving glycogen stores.
Adjustments can be made based on individual tolerance or specific periodization goals (e.g., slightly higher carbs pre?competition).
Implementation tips:
Meal timing ? Distribute protein across 4?6 meals, with ~20?25?g of high?quality protein per meal
for optimal muscle protein synthesis.
Recovery snack ? A post?training carbohydrate + protein combo (e.g., whey shake
+ banana) helps replenish glycogen and stimulate
repair within the anabolic window (~30?min).
Hydration & electrolytes ? Monitor sweat loss; supplement with sodium, potassium, and magnesium during heavy training days.
By following this plan, you’ll align your macronutrient intake with your training load, promoting muscle growth
while preventing excess fat gain. Adjust portion sizes as
needed based on body composition feedback every 4?6?weeks.
Good luck!
[2025-09-27 00:10:21.935892]
URL
(Von)
Ipamorelin, CJC-1295 And Cancer: Is There Any Evidence?
Ipamorelin, CJC?1295 and Cancer: Is There Any Evidence?
The combination of ipamorelin and CJC?1295 has gained popularity
among bodybuilders, athletes, and individuals seeking anti?aging benefits because
these peptides are thought to stimulate growth hormone (GH) release.
However, the potential link between GH stimulation and cancer development remains a topic of debate.
This article reviews current scientific knowledge about whether
ipamorelin or CJC?1295 can promote tumor growth
or increase cancer risk.
What is Ipamorelin and CJC-1295?
Ipamorelin is a synthetic hexapeptide that functions as a
selective growth hormone?releasing peptide (GHRP).
It binds to the ghrelin receptor on pituitary somatotroph cells, triggering the release of endogenous GH.
Because its structure mimics natural ghrelin but with higher selectivity and fewer
side effects, ipamorelin is used clinically for GH deficiency and
experimentally for muscle growth.
CJC?1295 (also known as REMD 477) is a synthetic analog of the growth hormone?releasing
hormone (GHRH). It contains a modified hexapeptide that has an extended
half?life due to attachment of a Cys?Asp?Glu?Trp (CDW) sequence, allowing it to resist enzymatic degradation. When combined with a
GHRP such as ipamorelin or hexarelin, the two peptides act synergistically: GHRH stimulates GH
secretion while GHRPs enhance the pituitary response.
Both agents are typically administered via subcutaneous injection and are regulated
by health authorities in many countries; they are
not approved for widespread therapeutic use outside of research settings.
Risk Factors of Ipamorelin and CJC-1295
The risk profile of these peptides is largely tied to their ability to
increase circulating GH levels. Elevated GH can lead to several physiological changes, including insulin?like growth factor
1 (IGF?1) production, altered glucose metabolism,
and potential effects on cellular proliferation.
The main concerns are:
Metabolic disturbances ? Hyperglycemia, dyslipidemia, or insulin resistance.
Cardiovascular effects ? Hypertension, fluid retention, or increased cardiac workload.
Hormonal imbalances ? Suppression of gonadotropins, altered thyroid function, or changes
in cortisol levels.
Potential oncogenic influence ? GH and IGF?1 can stimulate cell
division; whether this translates into higher cancer risk is uncertain.
Risk Factors of Ipamorelin
Ipamorelin’s safety data are derived from short?term clinical trials.
Adverse events reported include:
Mild injection site reactions (pain, erythema).
Transient increases in appetite or nausea.
Rare reports of headaches and dizziness.
Long?term safety studies are lacking, making it difficult to evaluate chronic
effects such as carcinogenesis.
Risk Factors of CJC-1295
CJC?1295 shares similar short?term side effect profiles but has been studied more extensively for its pharmacokinetics.
Reported adverse events include:
Injection site discomfort.
Transient fluid retention or edema.
Slight increases in insulin sensitivity,
which can be beneficial for metabolic health.
Again, data on long?term safety and cancer risk are insufficient.
Can Ipamorelin Cause Cancer?
The direct evidence linking ipamorelin to cancer development is minimal.
Animal studies have shown that chronic GH stimulation can promote tumor growth in specific contexts (e.g., insulin?responsive
tissues). However, these experiments often involve supraphysiological GH
levels or genetic predispositions that are not representative of typical human use.
In humans, large epidemiologic studies on GH?releasing peptides have not demonstrated a statistically significant
increase in cancer incidence. A review of post?marketing surveillance
reports found no consistent pattern suggesting ipamorelin as an oncogenic agent.
Nonetheless, because IGF?1 can act as a mitogen for many cell types, caution is advised for individuals with a history of hormone?sensitive cancers (breast, prostate, thyroid).
Can CJC 1295 Cause Cancer?
CJC?1295’s mechanism also elevates GH and IGF?1.
Some preclinical data indicate that prolonged exposure to
high IGF?1 levels can enhance the proliferation of certain cancer cell lines in vitro.
However, these findings are not necessarily predictive of clinical outcomes.
Human studies on CJC?1295 have focused on metabolic benefits and lack
evidence for increased tumor incidence. A few small trials reported no serious adverse events related to malignancy over periods of 6?12 months.
The absence of long?term data means that definitive conclusions cannot be drawn, but current literature does not support a strong causal link between CJC?1295 use and cancer.
Related Posts
Understanding Growth Hormone Therapy: Benefits and
Risks
How Peptides Influence Metabolism: A Deep Dive into GH?Releasing Peptides
The Role of IGF?1 in Cellular Proliferation and Cancer
Evaluating the Safety Profile of Bodybuilding Supplements
Managing Side Effects of Subcutaneous Peptide Injections
These resources provide further insight into peptide therapies, their physiological
impact, and how to approach potential risks responsibly.
Ipamorelin, CJC?1295 and Cancer: Is There Any Evidence?
The combination of ipamorelin and CJC?1295 has gained popularity
among bodybuilders, athletes, and individuals seeking anti?aging benefits because
these peptides are thought to stimulate growth hormone (GH) release.
However, the potential link between GH stimulation and cancer development remains a topic of debate.
This article reviews current scientific knowledge about whether
ipamorelin or CJC?1295 can promote tumor growth
or increase cancer risk.
What is Ipamorelin and CJC-1295?
Ipamorelin is a synthetic hexapeptide that functions as a
selective growth hormone?releasing peptide (GHRP).
It binds to the ghrelin receptor on pituitary somatotroph cells, triggering the release of endogenous GH.
Because its structure mimics natural ghrelin but with higher selectivity and fewer
side effects, ipamorelin is used clinically for GH deficiency and
experimentally for muscle growth.
CJC?1295 (also known as REMD 477) is a synthetic analog of the growth hormone?releasing
hormone (GHRH). It contains a modified hexapeptide that has an extended
half?life due to attachment of a Cys?Asp?Glu?Trp (CDW) sequence, allowing it to resist enzymatic degradation. When combined with a
GHRP such as ipamorelin or hexarelin, the two peptides act synergistically: GHRH stimulates GH
secretion while GHRPs enhance the pituitary response.
Both agents are typically administered via subcutaneous injection and are regulated
by health authorities in many countries; they are
not approved for widespread therapeutic use outside of research settings.
Risk Factors of Ipamorelin and CJC-1295
The risk profile of these peptides is largely tied to their ability to
increase circulating GH levels. Elevated GH can lead to several physiological changes, including insulin?like growth factor
1 (IGF?1) production, altered glucose metabolism,
and potential effects on cellular proliferation.
The main concerns are:
Metabolic disturbances ? Hyperglycemia, dyslipidemia, or insulin resistance.
Cardiovascular effects ? Hypertension, fluid retention, or increased cardiac workload.
Hormonal imbalances ? Suppression of gonadotropins, altered thyroid function, or changes
in cortisol levels.
Potential oncogenic influence ? GH and IGF?1 can stimulate cell
division; whether this translates into higher cancer risk is uncertain.
Risk Factors of Ipamorelin
Ipamorelin’s safety data are derived from short?term clinical trials.
Adverse events reported include:
Mild injection site reactions (pain, erythema).
Transient increases in appetite or nausea.
Rare reports of headaches and dizziness.
Long?term safety studies are lacking, making it difficult to evaluate chronic
effects such as carcinogenesis.
Risk Factors of CJC-1295
CJC?1295 shares similar short?term side effect profiles but has been studied more extensively for its pharmacokinetics.
Reported adverse events include:
Injection site discomfort.
Transient fluid retention or edema.
Slight increases in insulin sensitivity,
which can be beneficial for metabolic health.
Again, data on long?term safety and cancer risk are insufficient.
Can Ipamorelin Cause Cancer?
The direct evidence linking ipamorelin to cancer development is minimal.
Animal studies have shown that chronic GH stimulation can promote tumor growth in specific contexts (e.g., insulin?responsive
tissues). However, these experiments often involve supraphysiological GH
levels or genetic predispositions that are not representative of typical human use.
In humans, large epidemiologic studies on GH?releasing peptides have not demonstrated a statistically significant
increase in cancer incidence. A review of post?marketing surveillance
reports found no consistent pattern suggesting ipamorelin as an oncogenic agent.
Nonetheless, because IGF?1 can act as a mitogen for many cell types, caution is advised for individuals with a history of hormone?sensitive cancers (breast, prostate, thyroid).
Can CJC 1295 Cause Cancer?
CJC?1295’s mechanism also elevates GH and IGF?1.
Some preclinical data indicate that prolonged exposure to
high IGF?1 levels can enhance the proliferation of certain cancer cell lines in vitro.
However, these findings are not necessarily predictive of clinical outcomes.
Human studies on CJC?1295 have focused on metabolic benefits and lack
evidence for increased tumor incidence. A few small trials reported no serious adverse events related to malignancy over periods of 6?12 months.
The absence of long?term data means that definitive conclusions cannot be drawn, but current literature does not support a strong causal link between CJC?1295 use and cancer.
Related Posts
Understanding Growth Hormone Therapy: Benefits and
Risks
How Peptides Influence Metabolism: A Deep Dive into GH?Releasing Peptides
The Role of IGF?1 in Cellular Proliferation and Cancer
Evaluating the Safety Profile of Bodybuilding Supplements
Managing Side Effects of Subcutaneous Peptide Injections
These resources provide further insight into peptide therapies, their physiological
impact, and how to approach potential risks responsibly.
[2025-09-25 16:57:17.313118]
URL